APOE and Alzheimer disease: First, the results may be partially explained by factors that were not assessed such as a proportion of cases fulfilling preclinical AD criteria by virtue of an altered early biomarker (i.e., high levels of amyloid-β (Aβ) deposition), the presence of the APOE ɛ4 allele or dopamine depletion.